LEADER 03152nam  2200649Ia 450 
001 9910829990303321
005 20230725041325.0
010   $a1-282-38511-9
010   $a9786612385117
010   $a1-4443-1705-9
010   $a1-4443-1706-7
035   $a(CKB)1000000000822180
035   $a(EBL)470053
035   $a(SSID)ssj0000340039
035   $a(PQKBManifestationID)11215299
035   $a(PQKBTitleCode)TC0000340039
035   $a(PQKBWorkID)10387109
035   $a(PQKB)11609175
035   $a(MiAaPQ)EBC470053
035   $a(OCoLC)535814118
035   $a(EXLCZ)991000000000822180
100   $a20090728d2010      uy             0
101 0 $aeng
135   $aur|n|---|||||
181   $2rdacontent
182   $2rdamedia
183   $2rdacarrier
200 00$aMalignant liver tumors$b[electronic resource] $ecurrent and emerging therapies /$fedited by Pierre-Alain Clavien ; deputy editor, Stefan Breitenstein ; associate editors, Jacques Belghiti ... [et al.]
205   $a3rd ed.
210   $aChichester, West Sussex ;$aHoboken, NJ $cBlackwell$d2010
215   $a1 online resource (576 p.)
300   $aDescription based upon print version of record.
311   $a1-4051-7976-7 
320   $aIncludes bibliographical references and index.
327   $aMalignant Liver Tumors: Current and Emerging Therapies, THIRD EDITION; Contents; Contributors; Preface; Acknowledgments; Abbreviations; Section 1: Introduction; Section 2: Epidemiology and Diagnosis; Section 3: Systemic and Regional Therapies; Section 4: Resection, Ablation or Transplantation for Liver Tumors; Section 5: Guidelines for Liver Tumor Treatment; Section 6: Emerging Therapies; Section 7: Special Tumors, Population, and Special Considerations; Index
330   $aThis comprehensive and critical review of current and established treatment modalities for malignant liver tumors is designed to help you sort through the proliferation of competitive approaches and choose the best treatment options for your patient. Dr. Clavien and his contributors consider all the options - radiological, surgical, pharmaceutical, and emerging/novel therapies - and help you find the best single or combined therapy. Building on the success of the previous edition, this extremely thorough revision:features a new section on Guidelines for Liver Tumors, wh
606   $aLiver$xCancer$xTreatment
606   $aOncology
615  0$aLiver$xCancer$xTreatment.
615  0$aOncology.
676   $a616.99436
701   $aClavien$b Pierre-Alain$0878232
701   $aAbou-Alfa$b Ghassan$pMSKCC.$0878233
701   $aCassileth$b Barrie R$pMSKCC.$0878234
701   $aDai$b Menghua$pMSKCC.$0878235
701   $aFong$b Yuman$pMSKCC.$0878236
701   $aGonzalez$b Lorena$pMSKCC.$0878237
701   $aGubili$b Jyothirmai$pMSKCC.$0878238
701   $aKemeny$b Nancy$pMSKCC.$0878239
712 02$aMemorial Sloan Kettering Cancer Center (MSKCC).
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910829990303321
996   $aMalignant liver tumors$91960584
997   $aUNINA